Pfizer prepares for loss of drug exclusivity and raises 2026 revenue guidance
PFE Pfizer Inc
$28.28 +1.65%
View chart & analysis → - 1Pfizer (PFE) recorded a 17.5% stock return over the past 3 months.
- 2Pfizer management raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion.
- 3Pfizer's biopharma segment accounted for 98% of the company's revenue in fiscal year 2025.
So what's the key point?
Pfizer has raised its 2026 revenue forecast to around $62.5 billion. This means the company expects to earn more money in the future.
Source Trefis +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.